Skip to main content

Table 3 Characteristics of patients with early-stage (I and II) pure mucinous carcinoma of the breast

From: Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women

  Endocrine therapy P
   With chemotherapy (n = 41) Without chemotherapy (n = 37)  
Age, years,    <0.0001
  mean (SD) 43.85 (7.53) 58.15 (15.62)  
  median 44.54 59.54  
  range 28, 68 28, 85  
Tumor size, cm,    0.059
  mean (SD) 3.42 (2.62) 2.39 (1.93)  
  median 3.0 2.0  
  range 0.20, 17.0 0.20, 12.0  
Tumor stage, n, (%),    <0.0001
  T1 5 (13.51) 19 (52.78)  
  T2 28 (75.68) 15 (41.67)  
  Unknown or other 8 3  
grade, n (%),    1.000
  I 11 (73.33) 8 (66.67)  
  II 4 (26.67) 4 (33.33)  
  Unknown or other 26 25  
Stage, n (%)    <0.0001
  I 4 (11.76) 19 (55.88)  
  II 30 (88.24) 15 (44.12)  
Lymphovascular invasion, n (%),    0.018
  present 7 (28) 1 (3.33)  
  absent 18 (72) 29 (96.67)  
  unknown or other 16 7  
ER status, n (%),    0.112
  positive 35 (85.37) 36 (97.30)  
  negative 6 (14.63) 1 (2.70)  
PR status, n (%),    0.233
  positive 32 (78.05) 33 (89.19)  
  negative 9 (21.95) 4 (10.81)  
HER2 status, n (%),    0.199
  positive 5 (14.29) 1 (3.03)  
  negative 30 (85.71) 32 (96.97)  
  unknown or other 6 4  
Lymph node status, n (%),    0.013
  positive 11 (28.21) 2 (5.56)  
  negative 28 (71.79) 34 (94.44)  
  not evaluated 2 1  
Primary treatment, n (%),    0.056
  mastectomy 31 (77.50) 20 (54.05)  
  lumpectomy with RT 8 (20) 16 (43.24)  
  lumpectomy without RT 1 (2.50) 1 (2.70)  
  no surgery 1 0  
Follow up time, months    
  median 63 46  
  range 3, 139 9, 142  
10-year disease-free survival 87.90% 92.86% 0.529
10-year overall survival rate 88.82% 100% 0.156
  1. ER estrogen receptor, PR progesterone receptor, RT radiotherapy.